Press Release

Medios AG: Increase of free float through secondary placement envisaged - Admission to Prime Standard applied for

Berlin, 12 May 2020 - Medios AG, one of the leading Specialty Pharma companies in Germany, announces the placement of up to existing 600,000 shares. Half of these come from an employee stock option program launched by Tangaroa Management GmbH in 2016 and expiring at the end of 2020. Moreover, Manfred Schneider, CEO and indirect principal shareholder of Medios AG, will provide up to 300,000 additional own shares via Tangaroa GmbH & Co. KG for the placement. The up to 600,000 shares are to be offered today by M.M.Warburg & CO to institutional investors by way of an accelerated bookbuilding process within a private placement. There will be no dilution of the shareholders.

After the successful placement of all offered existing shares, the free float of Medios AG will increase from around 57% to around 61% of the share capital, which will help to improve the liquidity of the stock and support the admission to the SDAX.

Matthias Gärtner, CFO of Medios AG: "The secondary placement and the planned uplisting into the Prime Standard will bring us closer to our goal of being admitted to the SDAX as soon as possible. This would make our shares even more attractive for national and international investors."

Medios AG has already applied to Deutsche Börse for admission of its shares to a higher transparency level of the Regulated Market, the Prime Standard. To date, the shares are traded in the General Standard of the Regulated Market. The Management Board expects the admission within the next few weeks.

-------------------

About Medios AG
Medios AG is one of the leading Specialty Pharma companies in Germany. As a specialist for the provision of Specialty Pharma drugs to patients, GMP-certified provider of patient-specific therapies and innovative analytical methods, Medios covers substantial elements of the supply chain in this field and follows the highest international quality standards. Usually, Specialty Pharma drugs are high-priced medicines for rare and/or chronic diseases. Patient-specific therapies are, for example, infusions that are compiled and produced on the basis of individual diseases and parameters like body weight and surface. In the field of drug safety, NIR spectroscopic analysis methods (NIR: Near infrared) are used to distinguish marketable finished drugs from drug counterfeits. It is Medios' aim to provide integrated solutions along the value chain to partners and clients, thereby ensuring an optimal pharmaceutical care for patients.

Medios AG is Germany's first publicly listed Specialty Pharma company. The share (WKN: A1MMCC, ISIN: DE000A1MMCC8) is listed in the Regulated Market of the Frankfurt Stock Exchange (General Standard).

Contact
Kirchhoff Consult AG
Nikolaus Hammerschmidt
Borselstraße 20
22765 Hamburg
Germany
Phone: +49 40 60918618
Fax: +49 40 60918660
E-mail: nikolaus.hammerschmidt@kirchhoff.de
www.kirchhoff.de

Disclaimer
This release is for informational purposes only and does not constitute an offer or the announcement of a forthcoming offer or solicitation or invitation of any offer to buy any securities or the announcement of a forthcoming solicitation or invitation of any offer to buy any securities in any jurisdiction, including the United States, Australia, Canada or Japan. This release does not constitute investment advice or a recommendation to invest in shares of Medios AG.

No securities are offered by or on behalf of Medios AG. This release and the information it contains are not for publication in any jurisdiction in which it would be unlawful. In line with foreign securities laws, particularly the US Securities Act of 1933, as amended ("Securities Act"), shares of Medios AG have not been registered and will not be registered with foreign securities authorities and in particular may not be offered or sold in the United States of America ("USA") without registration or an exemption from the registration requirements of the Securities Act. This release may not be disseminated in the USA and/or within the USA and may not be distributed or forwarded to publications that are widely available in the USA.

In the United Kingdom, this release is only being distributed to and is only directed at persons who (i) are investment professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended) (the "Order") or (ii) are persons falling within Article 49(2)(a) to (e) (high net worth companies, unincorporated associations and other persons to whom it may lawfully be communicated) of the Order (all such persons together being referred to as "Relevant Persons"). This release is directed only at Relevant Persons and must not be acted on or relied on by persons who are not Relevant Persons. Any investment or investment activity to which this document relates is available only to Relevant Persons and will be engaged in only with Relevant Persons.

The shares of Medios AG are not intended to be offered, sold or otherwise made available to and should not be offered, sold or otherwise made available to any retail investor in the European Economic Area (the "EEA") or in the United Kingdom. For these purposes, a retail investor means a person who is one (or more) of: (i) a retail client as defined in point (11) of Article 4(1) of Directive 2014/65/EU, as amended ("MiFID II"); or (ii) a customer within the meaning of Directive (EU) 2016/97, as amended, where that customer would not qualify as a professional client as defined in point (10) of Article 4(1) of MiFID II; or (iii) not a qualified investor as defined in Regulation (EU) 2017/1129. Consequently no key information document required by Regulation (EU) No 1286/2014 (the "PRIIPs Regulation"), for offering or selling the shares of Medios AG or otherwise making them available to retail investors in the EEA or in the United Kingdom has been prepared and therefore offering or selling the shares of Medios AG, or otherwise making them available, to any retail investor in the EEA or in the United Kingdom may be unlawful under the PRIIPs Regulation.

This release contains forward-looking statements that are subject to certain risks and uncertainties. Future results may significantly deviate from currently expected results, specifically due to various risk factors and uncertainties such as changes in business, economic, and competitive circumstances, exchange rate fluctuations, uncertainties about legal disputes or investigations, and the availability of financial resources. Medios AG assumes no responsibility whatsoever for updating the forward-looking statements contained in this notification.